First-in-class humanized FSH blocking antibody targets bone and fat
Sakshi Gera(Icahn School of Medicine at Mount Sinai), Damini Sant(Icahn School of Medicine at Mount Sinai), Shozeb Haider(University College London), Funda Korkmaz(Icahn School of Medicine at Mount Sinai), Tan‐Chun Kuo(Icahn School of Medicine at Mount Sinai), Mehr Mathew(Icahn School of Medicine at Mount Sinai), Helena Pérez‐Peña(University College London), Honglin Xie, Hao Chen(Stanford University), Rogerio Batista(Icahn School of Medicine at Mount Sinai), Kejun Ma(Lanzhou University Second Hospital), Zhen Cheng(Stanford University), Elina Hadelia(Icahn School of Medicine at Mount Sinai), Cemre Robinson(Icahn School of Medicine at Mount Sinai), Anne Macdonald(Icahn School of Medicine at Mount Sinai), Sari Miyashita(Icahn School of Medicine at Mount Sinai), Anthony A. Williams(Icahn School of Medicine at Mount Sinai), Gregory Jebian(Icahn School of Medicine at Mount Sinai), Hirotaka Miyashita(Icahn School of Medicine at Mount Sinai), Anisa Gumerova(Icahn School of Medicine at Mount Sinai), Kseniia Ievleva(Icahn School of Medicine at Mount Sinai), Pinar J. Smith(Icahn School of Medicine at Mount Sinai), Jiahuan He(Stanford University), Vitaly Ryu(Icahn School of Medicine at Mount Sinai), Victoria DeMambro(Maine Medical Center Research Institute), Matthew Quinn(Wake Forest University), Marcia Meseck(Icahn School of Medicine at Mount Sinai), Se‐Min Kim(Icahn School of Medicine at Mount Sinai), T. Rajendra Kumar(University of Colorado Denver), Jameel Iqbal(Icahn School of Medicine at Mount Sinai), Maria I. New(Icahn School of Medicine at Mount Sinai), Daria Lizneva(Icahn School of Medicine at Mount Sinai), Clifford J. Rosen(Maine Medical Center Research Institute), Aaron J.W. Hsueh(Stanford University), Tony Yuen(Icahn School of Medicine at Mount Sinai), Mone Zaidi(Icahn School of Medicine at Mount Sinai)
Cited by 56Open Access
Abstract
Significance We report the development and characterization of a first-in-class humanized antibody to follicle-stimulating hormone (FSH). We have shown previously that blocking FSH action on its receptor increases bone mass, reduces body fat, and enhances energy expenditure. Furthermore, FSH has been reported to increase serum cholesterol. Therefore, an anti-FSH agent has the potential of preventing and treating obesity, osteoporosis, and hypercholesterolemia, diseases that affect millions of women and men worldwide. Our study provides the framework for further preclinical and subsequent clinical testing of our humanized antibody to FSH.
Related Papers
No related papers found
Powered by citation graph analysis